The impact of histologic tumor response on survival of patients treated with neoadjuvant mFOLFOX6 plus bevacizumab for the synchronous liver metastases from colorectal cancer.

被引：3
|
作者：
Katayose, Yu
Ishida, Kazuyuki
Nakagawa, Kei
Yamauchi, Junichiro
Oikawa, Masaya
Sakurai, Naoki
Musha, Hiroaki
Shimamura, Hiromune
Miura, Koh
Motoi, Fuyuhiko
Egawa, Shinichi
Unno, Michiaki
机构：
[1] Tohoku Univ, Grad Sch Med, Div Integrated Surg & Oncol, Sendai, Miyagi 980, Japan
[2] Iwate Med Univ, Dept Mol Diagnosit Pathol, Morioka, Iwate 020, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Sendai Open Hosp, Sendai, Miyagi, Japan
[5] Yamagata Prefectural Cent Hosp, Yamagata, Japan
[6] Tohoku Rosai Hosp, Sendai, Miyagi, Japan
[7] Sendai Med Ctr, Sendai, Miyagi, Japan
[8] Tohoku Univ, Grad Sch Med, Div Hepatobiliary & Pancreat Surg, Sendai, Miyagi 980, Japan
[9] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi 980, Japan
[10] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi 980, Japan
[11] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
625
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PATHOLOGICAL RESPONSE OF SYNCHRONOUS LIVER METASTASES FROM COLORECTAL CANCER TREATED WITH BEVACIZUMAB PLUS MFOLFOX6 IN AN ANALYSIS OF A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY
    Katayose, Y.
    Yamauchi, J.
    Oikawa, M.
    Sakurai, N.
    Musya, H.
    Shimamura, H.
    Miura, K.
    Nakagawa, K.
    Egawa, S.
    Unno, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 211 - 211
  • [2] Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
    Ushida, Yuta
    Shinozaki, Eiji
    Chin, Keisho
    Suenaga, Mitsukuni
    Takahari, Daisuke
    Ozaka, Masato
    Ogura, Mariko
    Ichimura, Takashi
    Wakatsuki, Takeru
    Yamaguchi, Kensei
    CASE REPORTS IN ONCOLOGY, 2018, 11 (02): : 601 - 608
  • [3] Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer
    Uehara, Keisuke
    Ishiguro, Seiji
    Hiramatsu, Kazuhiro
    Nishio, Hideki
    Takeuchi, Eiji
    Takahari, Daisuke
    Yoshioka, Yuichiro
    Takahashi, Yu
    Ebata, Tomoki
    Yoshimura, Kenichi
    Muro, Kei
    Nagino, Masato
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1229 - 1232
  • [4] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
  • [5] Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
    Emi, Y.
    Yamanaka, T.
    Muro, K.
    Uetake, H.
    Oki, E.
    Takahashi, T.
    Katayose, Y.
    Yoshida, K.
    Sakamoto, M.
    Aishima, S.
    Ishida, K.
    Imura, J.
    Unno, M.
    Hyodo, I.
    Tomita, N.
    Sugihara, K.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer.
    Shimada, M.
    Nishioka, M.
    Hanaoka, J.
    Mori, H.
    Ikemoto, T.
    Imura, S.
    Morine, Y.
    Utsunomiya, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] A PHASE II MULTICENTER TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH BEVACIZUMAB PLUS MFOLFOX6 FOR RESECTABLE CASES OF SYNCHRONOUS LIVER METASTASIS FROM COLORECTAL CANCER: THE FIRST INTERIM ANALYSIS
    Katayose, Y.
    Miura, K.
    Yamauchi, J.
    Sakurai, N.
    Musya, H.
    Oikawa, M.
    Uchiyama, T.
    Narushima, Y.
    Nakagawa, K.
    Unno, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 214 - 214
  • [8] Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer.
    Schirripa, M.
    Loupakis, F.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Fornaro, L.
    Campani, D.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Updated results of a phase II study of neoadjuvant chemotherapy with mFOLFOX6+bevacizumab for the synchronous liver metastases from colorectal cancer
    Nakagawa, K.
    Katayose, Y.
    Yamamoto, K.
    Yamauchi, J.
    Oikawa, M.
    Shimamura, H.
    Takahashi, K.
    Miura, K.
    Motoi, F.
    Unno, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S555 - S555
  • [10] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
    Van Cutsem, E.
    Prenen, H.
    Guillen-Ponce, C.
    Bennouna, J.
    Di Benedetto, M.
    Bouche, O.
    Staines, H.
    Oum'Hamed, Z.
    Studeny, M.
    Capdevila, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
12345